MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc.
Your view on MIRA
Overview
What the company does, where it operates, and who runs it.
About MIRA Pharmaceuticals, Inc.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Erez Aminov
- Headquarters
- 855 North Wolfe Street, Baltimore, MD, US
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Erez Aminov
- Headquarters
- 855 North Wolfe Street, Baltimore, MD, US
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company.
The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia.
It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for MIRA Pharmaceuticals, Inc. from FRC's valuation model, read against the market price. MIRA last traded at $0.59; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for MIRA Pharmaceuticals, Inc.. Starting points for MIRA Pharmaceuticals, Inc.: EPS -$0.23, beta 1.49 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for MIRA Pharmaceuticals, Inc.. MIRA Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for MIRA Pharmaceuticals, Inc.. Trailing twelve-month EPS for MIRA Pharmaceuticals, Inc. stands at -$0.23. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Analyst Ratings
- Strong Buy0
- Buy2
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.03 | -$0.04 | -$0.12 | -$0.16 |
| Low estimate | -$0.03 | -$0.04 | -$0.12 | -$0.16 |
| High estimate | -$0.03 | -$0.04 | -$0.12 | -$0.16 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | — | -$1.18 | -$1.351 | — |
| Growth | — | +96.6% | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | $0.00 | $276.00M | $40.00M |
| Low estimate | $0.00 | $0.00 | $276.00M | $40.00M |
| High estimate | $0.00 | $0.00 | $276.00M | $40.00M |
| No. of analysts | 0 | 0 | 1 | 1 |
| Year-ago revenue | — | $0.00 | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for MIRA Pharmaceuticals, Inc.. MIRA Pharmaceuticals, Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ANTXAN2 Therapeutics, Inc.Biotechnology$188M
- APUSApimeds Pharmaceuticals US, IncBiotechnology$3M
- IGCIGC Pharma, Inc.Biotechnology$23M
- MLSSMilestone Scientific Inc.Medical - Instruments & Supplies$23M
- MODDModular Medical, Inc.Medical - Devices$17M
- MYOMyomo, Inc.Medical - Devices$35M
- NNVCNanoViricides, Inc.Biotechnology$30M
- POCIPrecision Optics Corporation, Inc.Medical - Instruments & Supplies$46M
More Drug Manufacturers - General companies
- SCLXWScilex Holding CompanyNASDAQ$14M
- SNPHFSanten Pharmaceutical Co., Ltd.OTC$3.1B
- SNPHYSanten Pharmaceutical Co., Ltd.OTC$3.7B
- SNYSanofiNASDAQ$113.1B
- SNYNFSanofiOTC$115.1B
- TGRNFTong Ren Tang Technologies Co. Ltd.OTC$704M
- VRBCFVirbac S.A.OTC$2.9B
- ABBVAbbVie Inc.NYSE$505.5B
- ALPMFAstellas Pharma Inc.OTC$28.1B
- ALPMYAstellas Pharma Inc.OTC$29.2B
- AMGNAmgen Inc.NASDAQ$240.1B
- AMRNAmarin Corporation plcNASDAQ$233M
ETFs holding MIRA Pharmaceuticals, Inc.
% of the fund
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- IWCiShares Micro-Cap ETF$1.2B in assets0.01%
- VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
- VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets
- VGRO.TOVanguard Growth ETF Portfolio$10.9B in assets
- VBAL.TOVanguard Balanced ETF Portfolio$6.0B in assets
- VUS.TOVanguard U.S. Total Market Index ETF (CAD-hedged)$1.4B in assets0.00%
Largest holders first, then the funds most concentrated in MIRA.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold MIRA Pharmaceuticals, Inc., and how their positions are changing. At a $24.8M market value, institutional positions materially move MIRA Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by MIRA Pharmaceuticals, Inc. executives and directors. Shares of MIRA Pharmaceuticals, Inc. have traded between $0.73 and $2.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for MIRA Pharmaceuticals, Inc.. Coverage tracks MIRA Pharmaceuticals, Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of MIRA Pharmaceuticals, Inc.